Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34 + blood cells to pre-empt relapse in patients with CD34 + myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cel...
Gespeichert in:
| Veröffentlicht in: | Leukemia 2012-03, Vol.26 (3), p.381-389 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 389 |
|---|---|
| container_issue | 3 |
| container_start_page | 381 |
| container_title | Leukemia |
| container_volume | 26 |
| creator | Platzbecker, U Wermke, M Radke, J Oelschlaegel, U Seltmann, F Kiani, A Klut, I-M Knoth, H Röllig, C Schetelig, J Mohr, B Graehlert, X Ehninger, G Bornhäuser, M Thiede, C |
| description | This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34
+
blood cells to pre-empt relapse in patients with CD34
+
myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). At a median of 169 days after HSCT, 20/59 prospectively screened patients experienced a decrease of CD34
+
donor chimerism to |
| doi_str_mv | 10.1038/leu.2011.234 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3306138</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A283455743</galeid><sourcerecordid>A283455743</sourcerecordid><originalsourceid>FETCH-LOGICAL-c674t-d179839837f847e4f32d031aef317aa4c832c55e9946c7f3eab653af0a4745a03</originalsourceid><addsrcrecordid>eNptksFvFCEUxidGY9fqzbMhGvXirjDAwHgwmazVmmxjYuvFC6HsY5eGgRVmNPrXy2bXtmuaIRnC93vfg5evqp4SPCOYyrcexlmNCZnVlN2rJoSJZso5J_erCZZSTJu2ZkfVo5yvMN6KzcPqqCZSNkSQSfWr-6ONG9zSBUA2JjQk0EMPYUDRItf35bzsE3i9yYBcQGcfzlHhurMF2ujBFTUjbQdISHsfVxDAGXR6Pr94V6ry6ItcnIY1oK8ni-57Vzo47R9XD6z2GZ7s_8fVt48nF_PT6eLLp8_zbjE1jWDDdElEK2lZwkomgFlaLzElGiwlQmtmJK0N59C2rDHCUtCXDafaYs0E4xrT4-r9znczXvawNOW6SXu1Sa7X6beK2qlDJbi1WsWfilLcECqLweu9QYo_RsiD6l024L0OEMes2kYSQVvRFvL5f-RVHFMor1NtXW7FCa8L9GIHrbQH5YKNpavZWqqulpRxLhgt1OwOqnxL6J2JAawr5wcFr24VrEH7YZ2jHwcXQz4E3-xAk2LOCez1KAhW2zypkie1zZMqeSr4s9vju4b_BagAL_eAzkZ7m3QwLt9wXOBayu0YpzsuFymsIN0M587GfwG2vN9r</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>926535152</pqid></control><display><type>article</type><title>Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial</title><source>MEDLINE</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Platzbecker, U ; Wermke, M ; Radke, J ; Oelschlaegel, U ; Seltmann, F ; Kiani, A ; Klut, I-M ; Knoth, H ; Röllig, C ; Schetelig, J ; Mohr, B ; Graehlert, X ; Ehninger, G ; Bornhäuser, M ; Thiede, C</creator><creatorcontrib>Platzbecker, U ; Wermke, M ; Radke, J ; Oelschlaegel, U ; Seltmann, F ; Kiani, A ; Klut, I-M ; Knoth, H ; Röllig, C ; Schetelig, J ; Mohr, B ; Graehlert, X ; Ehninger, G ; Bornhäuser, M ; Thiede, C</creatorcontrib><description>This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34
+
blood cells to pre-empt relapse in patients with CD34
+
myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). At a median of 169 days after HSCT, 20/59 prospectively screened patients experienced a decrease of CD34
+
donor chimerism to <80% and received four azacitidine cycles (75 mg/m
2
/day for 7 days) while in complete hematologic remission. A total of 16 patients (80%) responded with either increasing CD34
+
donor chimerism to ⩾80% (
n
=10; 50%) or stabilization (
n
=6; 30%) in the absence of relapse. Stabilized patients and those with a later drop of CD34
+
donor chimerism to <80% after initial response were eligible for subsequent azacitidine cycles. A total of 11 patients (55%) received a median of 4 (range, 1–11) additional cycles. Eventually, hematologic relapse occurred in 13 patients (65%), but was delayed until a median of 231 days (range, 56–558) after initial decrease of CD34
+
donor chimerism to <80%. In conclusion, pre-emptive azacitidine treatment has an acceptable safety profile and can substantially prevent or delay hematologic relapse in patients with MDS or AML and MRD after allogeneic HSCT.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/leu.2011.234</identifier><identifier>PMID: 21886171</identifier><identifier>CODEN: LEUKED</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Azacitidine - adverse effects ; Azacitidine - therapeutic use ; Biological and medical sciences ; Bone marrow ; Cancer ; Cancer Research ; Care and treatment ; Chimerism ; Clinical trials ; Creatinine ; Critical Care Medicine ; Female ; Follow-Up Studies ; Graft versus host disease ; Hematologic and hematopoietic diseases ; Hematology ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Humans ; Intensive ; Internal Medicine ; Leading ; leading-article ; Leukemia ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - mortality ; Leukemia, Myeloid, Acute - therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Myelodysplastic syndromes ; Myelodysplastic Syndromes - drug therapy ; Myelodysplastic Syndromes - mortality ; Myelodysplastic Syndromes - therapy ; Neoplasm, Residual - therapy ; Oncology ; Recurrence ; Relapse ; Remission (Medicine) ; Stem cell transplantation ; Time Factors ; Transplantation ; Transplantation, Homologous ; Treatment Outcome ; Young Adult</subject><ispartof>Leukemia, 2012-03, Vol.26 (3), p.381-389</ispartof><rights>The Author(s) 2012</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2012 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Mar 2012</rights><rights>Copyright © 2012 Macmillan Publishers Limited 2012 Macmillan Publishers Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c674t-d179839837f847e4f32d031aef317aa4c832c55e9946c7f3eab653af0a4745a03</citedby><cites>FETCH-LOGICAL-c674t-d179839837f847e4f32d031aef317aa4c832c55e9946c7f3eab653af0a4745a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/leu.2011.234$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/leu.2011.234$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25702888$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21886171$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Platzbecker, U</creatorcontrib><creatorcontrib>Wermke, M</creatorcontrib><creatorcontrib>Radke, J</creatorcontrib><creatorcontrib>Oelschlaegel, U</creatorcontrib><creatorcontrib>Seltmann, F</creatorcontrib><creatorcontrib>Kiani, A</creatorcontrib><creatorcontrib>Klut, I-M</creatorcontrib><creatorcontrib>Knoth, H</creatorcontrib><creatorcontrib>Röllig, C</creatorcontrib><creatorcontrib>Schetelig, J</creatorcontrib><creatorcontrib>Mohr, B</creatorcontrib><creatorcontrib>Graehlert, X</creatorcontrib><creatorcontrib>Ehninger, G</creatorcontrib><creatorcontrib>Bornhäuser, M</creatorcontrib><creatorcontrib>Thiede, C</creatorcontrib><title>Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><description>This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34
+
blood cells to pre-empt relapse in patients with CD34
+
myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). At a median of 169 days after HSCT, 20/59 prospectively screened patients experienced a decrease of CD34
+
donor chimerism to <80% and received four azacitidine cycles (75 mg/m
2
/day for 7 days) while in complete hematologic remission. A total of 16 patients (80%) responded with either increasing CD34
+
donor chimerism to ⩾80% (
n
=10; 50%) or stabilization (
n
=6; 30%) in the absence of relapse. Stabilized patients and those with a later drop of CD34
+
donor chimerism to <80% after initial response were eligible for subsequent azacitidine cycles. A total of 11 patients (55%) received a median of 4 (range, 1–11) additional cycles. Eventually, hematologic relapse occurred in 13 patients (65%), but was delayed until a median of 231 days (range, 56–558) after initial decrease of CD34
+
donor chimerism to <80%. In conclusion, pre-emptive azacitidine treatment has an acceptable safety profile and can substantially prevent or delay hematologic relapse in patients with MDS or AML and MRD after allogeneic HSCT.</description><subject>Adult</subject><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Azacitidine - adverse effects</subject><subject>Azacitidine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Chimerism</subject><subject>Clinical trials</subject><subject>Creatinine</subject><subject>Critical Care Medicine</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graft versus host disease</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Leading</subject><subject>leading-article</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Myelodysplastic syndromes</subject><subject>Myelodysplastic Syndromes - drug therapy</subject><subject>Myelodysplastic Syndromes - mortality</subject><subject>Myelodysplastic Syndromes - therapy</subject><subject>Neoplasm, Residual - therapy</subject><subject>Oncology</subject><subject>Recurrence</subject><subject>Relapse</subject><subject>Remission (Medicine)</subject><subject>Stem cell transplantation</subject><subject>Time Factors</subject><subject>Transplantation</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptksFvFCEUxidGY9fqzbMhGvXirjDAwHgwmazVmmxjYuvFC6HsY5eGgRVmNPrXy2bXtmuaIRnC93vfg5evqp4SPCOYyrcexlmNCZnVlN2rJoSJZso5J_erCZZSTJu2ZkfVo5yvMN6KzcPqqCZSNkSQSfWr-6ONG9zSBUA2JjQk0EMPYUDRItf35bzsE3i9yYBcQGcfzlHhurMF2ujBFTUjbQdISHsfVxDAGXR6Pr94V6ry6ItcnIY1oK8ni-57Vzo47R9XD6z2GZ7s_8fVt48nF_PT6eLLp8_zbjE1jWDDdElEK2lZwkomgFlaLzElGiwlQmtmJK0N59C2rDHCUtCXDafaYs0E4xrT4-r9znczXvawNOW6SXu1Sa7X6beK2qlDJbi1WsWfilLcECqLweu9QYo_RsiD6l024L0OEMes2kYSQVvRFvL5f-RVHFMor1NtXW7FCa8L9GIHrbQH5YKNpavZWqqulpRxLhgt1OwOqnxL6J2JAawr5wcFr24VrEH7YZ2jHwcXQz4E3-xAk2LOCez1KAhW2zypkie1zZMqeSr4s9vju4b_BagAL_eAzkZ7m3QwLt9wXOBayu0YpzsuFymsIN0M587GfwG2vN9r</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Platzbecker, U</creator><creator>Wermke, M</creator><creator>Radke, J</creator><creator>Oelschlaegel, U</creator><creator>Seltmann, F</creator><creator>Kiani, A</creator><creator>Klut, I-M</creator><creator>Knoth, H</creator><creator>Röllig, C</creator><creator>Schetelig, J</creator><creator>Mohr, B</creator><creator>Graehlert, X</creator><creator>Ehninger, G</creator><creator>Bornhäuser, M</creator><creator>Thiede, C</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20120301</creationdate><title>Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial</title><author>Platzbecker, U ; Wermke, M ; Radke, J ; Oelschlaegel, U ; Seltmann, F ; Kiani, A ; Klut, I-M ; Knoth, H ; Röllig, C ; Schetelig, J ; Mohr, B ; Graehlert, X ; Ehninger, G ; Bornhäuser, M ; Thiede, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c674t-d179839837f847e4f32d031aef317aa4c832c55e9946c7f3eab653af0a4745a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Azacitidine - adverse effects</topic><topic>Azacitidine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Chimerism</topic><topic>Clinical trials</topic><topic>Creatinine</topic><topic>Critical Care Medicine</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graft versus host disease</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Leading</topic><topic>leading-article</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Myelodysplastic syndromes</topic><topic>Myelodysplastic Syndromes - drug therapy</topic><topic>Myelodysplastic Syndromes - mortality</topic><topic>Myelodysplastic Syndromes - therapy</topic><topic>Neoplasm, Residual - therapy</topic><topic>Oncology</topic><topic>Recurrence</topic><topic>Relapse</topic><topic>Remission (Medicine)</topic><topic>Stem cell transplantation</topic><topic>Time Factors</topic><topic>Transplantation</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Platzbecker, U</creatorcontrib><creatorcontrib>Wermke, M</creatorcontrib><creatorcontrib>Radke, J</creatorcontrib><creatorcontrib>Oelschlaegel, U</creatorcontrib><creatorcontrib>Seltmann, F</creatorcontrib><creatorcontrib>Kiani, A</creatorcontrib><creatorcontrib>Klut, I-M</creatorcontrib><creatorcontrib>Knoth, H</creatorcontrib><creatorcontrib>Röllig, C</creatorcontrib><creatorcontrib>Schetelig, J</creatorcontrib><creatorcontrib>Mohr, B</creatorcontrib><creatorcontrib>Graehlert, X</creatorcontrib><creatorcontrib>Ehninger, G</creatorcontrib><creatorcontrib>Bornhäuser, M</creatorcontrib><creatorcontrib>Thiede, C</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Platzbecker, U</au><au>Wermke, M</au><au>Radke, J</au><au>Oelschlaegel, U</au><au>Seltmann, F</au><au>Kiani, A</au><au>Klut, I-M</au><au>Knoth, H</au><au>Röllig, C</au><au>Schetelig, J</au><au>Mohr, B</au><au>Graehlert, X</au><au>Ehninger, G</au><au>Bornhäuser, M</au><au>Thiede, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>26</volume><issue>3</issue><spage>381</spage><epage>389</epage><pages>381-389</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><coden>LEUKED</coden><abstract>This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34
+
blood cells to pre-empt relapse in patients with CD34
+
myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). At a median of 169 days after HSCT, 20/59 prospectively screened patients experienced a decrease of CD34
+
donor chimerism to <80% and received four azacitidine cycles (75 mg/m
2
/day for 7 days) while in complete hematologic remission. A total of 16 patients (80%) responded with either increasing CD34
+
donor chimerism to ⩾80% (
n
=10; 50%) or stabilization (
n
=6; 30%) in the absence of relapse. Stabilized patients and those with a later drop of CD34
+
donor chimerism to <80% after initial response were eligible for subsequent azacitidine cycles. A total of 11 patients (55%) received a median of 4 (range, 1–11) additional cycles. Eventually, hematologic relapse occurred in 13 patients (65%), but was delayed until a median of 231 days (range, 56–558) after initial decrease of CD34
+
donor chimerism to <80%. In conclusion, pre-emptive azacitidine treatment has an acceptable safety profile and can substantially prevent or delay hematologic relapse in patients with MDS or AML and MRD after allogeneic HSCT.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21886171</pmid><doi>10.1038/leu.2011.234</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2012-03, Vol.26 (3), p.381-389 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3306138 |
| source | MEDLINE; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Azacitidine - adverse effects Azacitidine - therapeutic use Biological and medical sciences Bone marrow Cancer Cancer Research Care and treatment Chimerism Clinical trials Creatinine Critical Care Medicine Female Follow-Up Studies Graft versus host disease Hematologic and hematopoietic diseases Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Intensive Internal Medicine Leading leading-article Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Medicine Medicine & Public Health Middle Aged Myelodysplastic syndromes Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - mortality Myelodysplastic Syndromes - therapy Neoplasm, Residual - therapy Oncology Recurrence Relapse Remission (Medicine) Stem cell transplantation Time Factors Transplantation Transplantation, Homologous Treatment Outcome Young Adult |
| title | Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A46%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Azacitidine%20for%20treatment%20of%20imminent%20relapse%20in%20MDS%20or%20AML%20patients%20after%20allogeneic%20HSCT:%20results%20of%20the%20RELAZA%20trial&rft.jtitle=Leukemia&rft.au=Platzbecker,%20U&rft.date=2012-03-01&rft.volume=26&rft.issue=3&rft.spage=381&rft.epage=389&rft.pages=381-389&rft.issn=0887-6924&rft.eissn=1476-5551&rft.coden=LEUKED&rft_id=info:doi/10.1038/leu.2011.234&rft_dat=%3Cgale_pubme%3EA283455743%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=926535152&rft_id=info:pmid/21886171&rft_galeid=A283455743&rfr_iscdi=true |